Table II.
Association between MIR100HG expression and clinicopathological characteristics of patients with colorectal cancer.
| Relative MIR100HG expression | ||||
|---|---|---|---|---|
| Variables | Number (%) | Low, n (n=37, %) | High, n (n=79, %) | P-value |
| Age, years | 0.596 | |||
| <65 | 54 (46.2) | 20 (54.1) | 34 (43.0) | |
| ≥65 | 62 (53.8) | 17 (45.9) | 45 (57.0) | |
| Sex | 0.629 | |||
| Male | 60 (51.7) | 16 (43.2) | 44 (55.7) | |
| Female | 56 (48.3) | 21 (56.8) | 35 (44.3) | |
| Tumor size, cm | 0.067 | |||
| <3 | 62 (53.4) | 25 (67.6) | 37 (46.8) | |
| ≥3 | 54 (46.6) | 12 (32.4) | 42 (53.2) | |
| Location | 0.416 | |||
| Right | 29 (25.0) | 6 (16.2) | 23 (29.1) | |
| Transverse | 27 (23.3) | 17 (45.9) | 10 (12.7) | |
| Left | 60 (51.7) | 14 (37.9) | 46 (58.2) | |
| AJCC stage | 0.024a | |||
| I–II | 45 (38.8) | 24 (64.9) | 21 (26.6) | |
| III–IV | 71 (61.2) | 13 (35.1) | 58 (73.4) | |
| pT stage | 0.048a | |||
| T1 | 17 (14.6) | 10 (27.0) | 7 (8.9) | |
| T2 | 46 (39.7) | 12 (32.4) | 34 (43.0) | |
| T3 | 37 (31.9) | 11 (29.8) | 26 (32.9) | |
| T4 | 16 (13.8) | 4 (10.8) | 12 (15.2) | |
| pN stage | 0.020a | |||
| N0 | 45 (38.8) | 24 (64.9) | 21 (26.6) | |
| N1-2 | 71 (61.2) | 13 (35.1) | 58 (73.4) | |
| pM stage | 0.023a | |||
| M0 | 101 (87.1) | 37 (100) | 64 (81.0) | |
| M1 | 15 (12.9) | 0 (0.0) | 15 (19.0) | |
| Differentiation | 0.035a | |||
| Well | 31 (26.7) | 19 (51.4) | 12 (15.2) | |
| Moderate | 40 (34.5) | 10 (27.0) | 30 (38.0) | |
| Poor | 45 (38.8) | 8 (21.6) | 37 (46.8) | |
| Vascular invasion | 0.862 | |||
| Yes | 3 (2.6) | 0 (0.0) | 3 (3.8) | |
| No | 113 (97.4) | 37 (100) | 76 (96.2) | |
a
P<0.05. AJCC, American Joint Committee on Cancer; MIR100HG, mir-100-let-7a-2-mir-125b-1 cluster host gene.